Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Daxor's BVA Technology Shown to Provide Unique and Individualized Data for Patient Management
Oak Ridge, TN, May 18, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces new data demonstrating the importance and clinical utility of Daxor's BVA-100 blood test in heart failure patients published in the European Society of Cardiology Heart Failure. The results of the study demonstrated Daxor's blood volume analysis (BVA) provides unique and individualized data that is critical for targeting heart failure therapy and is predictive of clinical outcomes.
The study titled, "Differences in Red Blood Cell Mass Profiles Impact Intravascular Volume and Outcome Risk in Chronic Heart Failure," studied the differences in total blood volume and red blood cell mass – two critical treatment targets in patients who were considered clinically stable and their impact on clinical outcomes in chronic heart failure. Both measures were determined using Daxor's innovative BVA technology. The results showed that survival rates of patients could be predicted with blood volume analysis via Daxor's test from their red blood cell levels.
Wayne L. Miller, M.D., Department of Cardiovascular Disease, Mayo Clinic, Rochester, MN, lead author of the study, concluded, "The findings of this study demonstrate that patients with chronic heart failure develop marked differences in profiles despite comparable stable clinical status, and that this variability has significant associations with the important clinical outcomes of heart failure-related mortality and hospitalizations."
"Our test uniquely informs clinicians with two important treatment targets to help individualize and treat volume derangements in complex heart failure patients," said Michael Feldschuh, CEO of Daxor Corporation. "Past studies in peer-reviewed journals have shown substantial improvements in mortality reduction, hospital readmission, and costs from the use of our diagnostic."
Posted In: DXR